292 related articles for article (PubMed ID: 34046693)
21. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
[TBL] [Abstract][Full Text] [Related]
22. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
23. Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.
Tarkkonen KM; Nilsson EM; Kähkönen TE; Dey JH; Heikkilä JE; Tuomela JM; Liu Q; Hynes NE; Härkönen PL
PLoS One; 2012; 7(11):e49970. PubMed ID: 23185502
[TBL] [Abstract][Full Text] [Related]
24. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
[TBL] [Abstract][Full Text] [Related]
25. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
26. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review.
de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET
Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904
[TBL] [Abstract][Full Text] [Related]
27. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression.
de Almeida Magalhães T; Cruzeiro GAV; de Sousa GR; da Silva KR; Lira RCP; Scrideli CA; Tone LG; Valera ET; Borges KS
Cancer Gene Ther; 2020 Jun; 27(6):509-512. PubMed ID: 31308481
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes.
Yan D; Chen D; Cool SM; van Wijnen AJ; Mikecz K; Murphy G; Im HJ
Arthritis Res Ther; 2011 Aug; 13(4):R130. PubMed ID: 21835001
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782
[TBL] [Abstract][Full Text] [Related]
30. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract][Full Text] [Related]
31. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
32. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
[TBL] [Abstract][Full Text] [Related]
33. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
[TBL] [Abstract][Full Text] [Related]
35. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
Wang Q; Green RP; Zhao G; Ornitz DM
Development; 2001 Oct; 128(19):3867-76. PubMed ID: 11585811
[TBL] [Abstract][Full Text] [Related]
36. Expression of fibroblast growth factor receptor 3 by fibroblast growth factor 2 in cultured chick embryo chondrocytes.
Suh JY; Kim YS; Park JW; Sonn JK; Kim WT
Cell Biol Int; 2005 Mar; 29(3):203-12. PubMed ID: 15878293
[TBL] [Abstract][Full Text] [Related]
37. Strong OLIG2 expression in supratentorial ependymoma, ZFTA fusion-positive: A potential diagnostic pitfall.
de Castro JVA; Kulikowski LD; Wolff BM; Natalino R; Carraro DM; Torrezan GT; Scapulatempo Neto C; Amancio CT; Canedo FSNA; Feher O; Costa FD
Neuropathology; 2024 Apr; 44(2):167-172. PubMed ID: 37855183
[TBL] [Abstract][Full Text] [Related]
38. Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer.
Brown WS; Tan L; Smith A; Gray NS; Wendt MK
Mol Cancer Ther; 2016 Sep; 15(9):2096-106. PubMed ID: 27371729
[TBL] [Abstract][Full Text] [Related]
39. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity.
Chellaiah A; Yuan W; Chellaiah M; Ornitz DM
J Biol Chem; 1999 Dec; 274(49):34785-94. PubMed ID: 10574949
[TBL] [Abstract][Full Text] [Related]
40. Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.
Upadhyaya SA; Robinson GW; Onar-Thomas A; Orr BA; Billups CA; Bowers DC; Bendel AE; Hassall T; Crawford JR; Partap S; Fisher PG; Tatevossian RG; Seah T; Qaddoumi IA; Vinitsky A; Armstrong GT; Sabin ND; Tinkle CL; Klimo P; Indelicato DJ; Boop FA; Merchant TE; Ellison DW; Gajjar A
Neuro Oncol; 2019 Oct; 21(10):1319-1330. PubMed ID: 30976811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]